MIRTAZAPINE
16 general benefit · 8 not a benefit
Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable
- Duloxetine (Cymbalta): general benefit, Not a benefit
- Trazodone (Desyrel): general benefit, Not a benefit
- Venlafaxine (Effexor XR): general benefit
- Vortioxetine (Trintellix): general benefit
- Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
- Desvenlafaxine (Pristiq): not a benefit
17 more in the class list below
Auro-Mirtazapine OD · DIN 02299801 · 15mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Mirtazapine OD · DIN 02299801
Manufacturer: Auro Pharma Inc.; listing date 2011-06-08
Health Canada: Marketed since 2010-12-20 · brand AURO-MIRTAZAPINE OD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 15 MG · company Auro pharma inc · schedule Prescription
Auro-Mirtazapine OD: Formulary list price $0.4046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78516 · Verify on the e-Formulary ↗ (DIN 02299801)
Source record
DIN 02299801: Auro-Mirtazapine OD
Raw flags: sec3=Y
Item: 281604112; group id 464; item number 1164; lccId None; manufacturer id AUR
Source form: Orally Disintegrating Tab; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.4046; ministry $0.4046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299801
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78516
Interchangeable products
Remeron RD · DIN 02248542 · $0.4046
Shortage status: resolved shortage (ended 2024-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299801
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Remeron RD · DIN 02248542 · 15mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron RD · DIN 02248542
Manufacturer: Organon Canada Inc.; listing date 2005-02-22
Health Canada: Marketed since 2022-05-24 · brand REMERON RD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 15 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.4046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72897 · Verify on the e-Formulary ↗ (DIN 02248542)
Source record
DIN 02248542: Remeron RD
Raw flags: sec3=Y
Item: 281604112; group id 464; item number 1164; lccId None; manufacturer id OCI
Source form: Orally Disintegrating Tab; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.5529; ministry $0.4046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248542
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72897
Interchangeable products
Auro-Mirtazapine OD · DIN 02299801 · $0.4046
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248542
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Mirtazapine OD · DIN 02299828 · 30mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Mirtazapine OD · DIN 02299828
Manufacturer: Auro Pharma Inc.; listing date 2011-06-08
Health Canada: Marketed since 2010-12-20 · brand AURO-MIRTAZAPINE OD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 30 MG · company Auro pharma inc · schedule Prescription
Auro-Mirtazapine OD: Formulary list price $0.8087/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8087 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78517 · Verify on the e-Formulary ↗ (DIN 02299828)
Source record
DIN 02299828: Auro-Mirtazapine OD
Raw flags: sec3=Y
Item: 281604113; group id 464; item number 1165; lccId None; manufacturer id AUR
Source form: Orally Disintegrating Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.8087; ministry $0.8087
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299828
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78517
Interchangeable products
Remeron RD · DIN 02248543 · $0.8087
Shortage status: resolved shortage (ended 2022-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299828
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Remeron RD · DIN 02248543 · 30mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron RD · DIN 02248543
Manufacturer: Organon Canada Inc.; listing date 2005-02-22
Health Canada: Marketed since 2022-08-04 · brand REMERON RD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 30 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.8087 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72898 · Verify on the e-Formulary ↗ (DIN 02248543)
Source record
DIN 02248543: Remeron RD
Raw flags: sec3=Y
Item: 281604113; group id 464; item number 1165; lccId None; manufacturer id OCI
Source form: Orally Disintegrating Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $1.1052; ministry $0.8087
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248543
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72898
Interchangeable products
Auro-Mirtazapine OD · DIN 02299828 · $0.8087
Shortage status: resolved shortage (ended 2022-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248543
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Mirtazapine · DIN 02286629 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Mirtazapine · DIN 02286629
Manufacturer: Apotex Inc.; listing date 2007-01-02
Health Canada: Marketed since 2006-10-04 · brand APO-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Apotex inc · schedule Prescription
Apo-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77207 · Verify on the e-Formulary ↗ (DIN 02286629)
Source record
DIN 02286629: Apo-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id APX
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286629
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77207
Interchangeable products
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2024-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02286629
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Mirtazapine · DIN 02411709 · 30mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Mirtazapine · DIN 02411709
Manufacturer: Auro Pharma Inc.; listing date 2014-01-03
Health Canada: Marketed since 2013-10-16 · brand AURO-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Auro pharma inc · schedule Prescription
Auro-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89630 · Verify on the e-Formulary ↗ (DIN 02411709)
Source record
DIN 02411709: Auro-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id AUR
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411709
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89630
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2024-08-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411709
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mirtazapine · DIN 02370689 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mirtazapine · DIN 02370689
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2025-10-28 · brand MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Sanis health inc · schedule Prescription
Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85581 · Verify on the e-Formulary ↗ (DIN 02370689)
Source record
DIN 02370689: Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id SAI
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02370689
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85581
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2025-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370689
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mirtazapine · DIN 02496674 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mirtazapine · DIN 02496674
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18
Health Canada: Marketed since 2020-10-22 · brand MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98653 · Verify on the e-Formulary ↗ (DIN 02496674)
Source record
DIN 02496674: Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id SIV
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496674
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98653
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496674
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Mirtazapine · DIN 02256118 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mylan-Mirtazapine · DIN 02256118
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2004-09-14
Health Canada: Marketed since 2009-10-09 · brand MYLAN-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74134 · Verify on the e-Formulary ↗ (DIN 02256118)
Source record
DIN 02256118: Mylan-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id MYL
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256118
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74134
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2025-12-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02256118
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Mirtazapine · DIN 02534932 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Mirtazapine · DIN 02534932
Manufacturer: Nora Pharma; listing date 2023-09-28
Health Canada: Marketed since 2023-07-27 · brand NRA-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Nora pharma inc · schedule Prescription
NRA-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102382 · Verify on the e-Formulary ↗ (DIN 02534932)
Source record
DIN 02534932: NRA-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id NRA
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534932
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102382
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534932
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Remeron · DIN 02243910 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron · DIN 02243910
Manufacturer: Organon Canada Inc.; listing date 2002-07-29
Health Canada: Marketed since 2022-05-17 · brand REMERON · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852 · Verify on the e-Formulary ↗ (DIN 02243910)
Source record
DIN 02243910: Remeron
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id OCI
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $1.8987; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243910
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2019-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243910
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Mirtazapine · DIN 02250608 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Mirtazapine · DIN 02250608
Manufacturer: Sandoz Canada Inc.; listing date 2004-07-20
Health Canada: Marketed since 2006-01-27 · brand SANDOZ MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73541 · Verify on the e-Formulary ↗ (DIN 02250608)
Source record
DIN 02250608: Sandoz Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id SDZ
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250608
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73541
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2023-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02250608
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mirtazapine · DIN 02259354 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Mirtazapine · DIN 02259354
Manufacturer: Teva Canada Limited; listing date 2004-12-21
Health Canada: Marketed since 2023-09-18 · brand TEVA-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Teva canada limited · schedule Prescription
Teva-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74461 · Verify on the e-Formulary ↗ (DIN 02259354)
Source record
DIN 02259354: Teva-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id TEV
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02259354
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74461
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
PMS-Mirtazapine · DIN 02248762 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02259354
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Mirtazapine OD · DIN 02299836 · 45mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Mirtazapine OD · DIN 02299836
Manufacturer: Auro Pharma Inc.; listing date 2011-06-08
Health Canada: Marketed since 2010-12-20 · brand AURO-MIRTAZAPINE OD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 45 MG · company Auro pharma inc · schedule Prescription
Auro-Mirtazapine OD: Formulary list price $1.2132/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2132 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78518 · Verify on the e-Formulary ↗ (DIN 02299836)
Source record
DIN 02299836: Auro-Mirtazapine OD
Raw flags: sec3=Y
Item: 281604114; group id 464; item number 1166; lccId None; manufacturer id AUR
Source form: Orally Disintegrating Tab; strength: 45mg
Recorded listing: General benefit
Source prices (unrounded): $1.2132; ministry $1.2132
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299836
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78518
Interchangeable products
Remeron RD · DIN 02248544 · $1.2132
Shortage status: resolved shortage (ended 2022-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299836
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Remeron RD · DIN 02248544 · 45mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron RD · DIN 02248544
Manufacturer: Organon Canada Inc.; listing date 2005-02-22
Health Canada: Marketed since 2022-11-04 · brand REMERON RD · ATC N06AX11 MIRTAZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients MIRTAZAPINE 45 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $1.2132 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72899 · Verify on the e-Formulary ↗ (DIN 02248544)
Source record
DIN 02248544: Remeron RD
Raw flags: sec3=Y
Item: 281604114; group id 464; item number 1166; lccId None; manufacturer id OCI
Source form: Orally Disintegrating Tab; strength: 45mg
Recorded listing: General benefit
Source prices (unrounded): $1.6580; ministry $1.2132
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248544
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72899
Interchangeable products
Auro-Mirtazapine OD · DIN 02299836 · $1.2132
Shortage status: resolved shortage (ended 2023-03-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248544
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Mirtazapine · DIN 02411695 · 15mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Mirtazapine · DIN 02411695
Manufacturer: Auro Pharma Inc.; listing date 2025-01-31
Health Canada: Marketed since 2013-10-16 · brand AURO-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 15 MG · company Auro pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89629 · Verify on the e-Formulary ↗ (DIN 02411695)
Source record
DIN 02411695: Auro-Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604138; group id 464; item number 1167; lccId None; manufacturer id AUR
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411695
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89629
Interchangeable products
Mirtazapine · DIN 02496666 · not recorded
Mirtazapine · DIN 02532689 · not recorded
Remeron · DIN 02243909 · not recorded
Teva-Mirtazapine · DIN 02541572 · not recorded
Shortage status: resolved shortage (ended 2024-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411695
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mirtazapine · DIN 02496666 · 15mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mirtazapine · DIN 02496666
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-03-31
Health Canada: Marketed since 2020-10-22 · brand MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 15 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98652 · Verify on the e-Formulary ↗ (DIN 02496666)
Source record
DIN 02496666: Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604138; group id 464; item number 1167; lccId None; manufacturer id SIV
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496666
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98652
Interchangeable products
Auro-Mirtazapine · DIN 02411695 · not recorded
Mirtazapine · DIN 02532689 · not recorded
Remeron · DIN 02243909 · not recorded
Teva-Mirtazapine · DIN 02541572 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496666
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mirtazapine · DIN 02532689 · 15mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mirtazapine · DIN 02532689
Manufacturer: Sanis Health Inc.; listing date 2025-07-31
Health Canada: Marketed since 2023-10-12 · brand MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 15 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102170 · Verify on the e-Formulary ↗ (DIN 02532689)
Source record
DIN 02532689: Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604138; group id 464; item number 1167; lccId None; manufacturer id SAI
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02532689
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102170
Interchangeable products
Auro-Mirtazapine · DIN 02411695 · not recorded
Mirtazapine · DIN 02496666 · not recorded
Remeron · DIN 02243909 · not recorded
Teva-Mirtazapine · DIN 02541572 · not recorded
Shortage status: resolved shortage (ended 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02532689
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mirtazapine · DIN 02541572 · 15mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Mirtazapine · DIN 02541572
Manufacturer: Teva Canada Limited; listing date 2024-10-31
Health Canada: Marketed since 2024-09-03 · brand TEVA-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 15 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103021 · Verify on the e-Formulary ↗ (DIN 02541572)
Source record
DIN 02541572: Teva-Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604138; group id 464; item number 1167; lccId None; manufacturer id TEV
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541572
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103021
Interchangeable products
Auro-Mirtazapine · DIN 02411695 · not recorded
Mirtazapine · DIN 02496666 · not recorded
Mirtazapine · DIN 02532689 · not recorded
Remeron · DIN 02243909 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541572
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Mirtazapine · DIN 02411717 · 45mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Mirtazapine · DIN 02411717
Manufacturer: Auro Pharma Inc.; listing date 2025-01-31
Health Canada: Marketed since 2013-10-16 · brand AURO-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 45 MG · company Auro pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89632 · Verify on the e-Formulary ↗ (DIN 02411717)
Source record
DIN 02411717: Auro-Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604139; group id 464; item number 1169; lccId None; manufacturer id AUR
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1250; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411717
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89632
Interchangeable products
Mirtazapine · DIN 02496682 · not recorded
Remeron · DIN 02243911 · not recorded
Teva-Mirtazapine · DIN 02541580 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411717
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mirtazapine · DIN 02496682 · 45mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mirtazapine · DIN 02496682
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-03-31
Health Canada: Marketed since 2020-10-22 · brand MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 45 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98654 · Verify on the e-Formulary ↗ (DIN 02496682)
Source record
DIN 02496682: Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604139; group id 464; item number 1169; lccId None; manufacturer id SIV
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1250; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496682
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98654
Interchangeable products
Auro-Mirtazapine · DIN 02411717 · not recorded
Remeron · DIN 02243911 · not recorded
Teva-Mirtazapine · DIN 02541580 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496682
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mirtazapine · DIN 02541580 · 45mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Mirtazapine · DIN 02541580
Manufacturer: Teva Canada Limited; listing date 2024-10-31
Health Canada: Marketed since 2024-09-03 · brand TEVA-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 45 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103022 · Verify on the e-Formulary ↗ (DIN 02541580)
Source record
DIN 02541580: Teva-Mirtazapine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604139; group id 464; item number 1169; lccId None; manufacturer id TEV
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1250; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541580
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103022
Interchangeable products
Auro-Mirtazapine · DIN 02411717 · not recorded
Mirtazapine · DIN 02496682 · not recorded
Remeron · DIN 02243911 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541580
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Mirtazapine · DIN 02248762 · 30mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Mirtazapine · DIN 02248762
Manufacturer: Pharmascience Inc.; listing date 2004-07-20
Health Canada: Dormant since 2025-08-01 · brand PMS-MIRTAZAPINE · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Pharmascience inc · schedule Prescription
PMS-Mirtazapine: Formulary list price $0.3100/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3100 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73130 · Verify on the e-Formulary ↗ (DIN 02248762)
Source record
DIN 02248762: PMS-Mirtazapine
Raw flags: sec3=Y
Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id PMS
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3100; ministry $0.3100
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248762
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73130
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100
Auro-Mirtazapine · DIN 02411709 · $0.3100
Mirtazapine · DIN 02370689 · $0.3100
Mirtazapine · DIN 02496674 · $0.3100
Mylan-Mirtazapine · DIN 02256118 · $0.3100
NRA-Mirtazapine · DIN 02534932 · $0.3100
Remeron · DIN 02243910 · $0.3100
Sandoz Mirtazapine · DIN 02250608 · $0.3100
Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: active shortage (reported 2023-05-29, estimated to end 2027-01-01, last updated 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248762
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.
Remeron · PIN 02243909 · 15mg · tablet
Off-Formulary Interchangeable, not an ODB benefitOntario PIN; no Health Canada record under this code
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02243910 (Marketed, 2022-05-17)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852
Check Health Canada brand DINPrivate plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron · DIN 02243909
Manufacturer: Organon Canada Ltd./Ltee; listing date 2024-10-31
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02243910 (Marketed, 2022-05-17)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852
Remeron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 02243909)
Source record
DIN 02243909: Remeron
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604138; group id 464; item number 1167; lccId None; manufacturer id ORG
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243909
Health Canada record for this brand: DIN 02243910 (Marketed, 2022-05-17)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852
Interchangeable products
Auro-Mirtazapine · DIN 02411695 · not recorded
Mirtazapine · DIN 02496666 · not recorded
Mirtazapine · DIN 02532689 · not recorded
Teva-Mirtazapine · DIN 02541572 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243909
Shortage record checked 2026-09-13T08:10:21.292534+00:00